A Current and Future Perspective on Adjuvant and Neoadjuvant Recirculating Chemohyperthermia as a Treatment for Intermediate-High Risk NMIBC
Nearly 75% of bladder cancer diagnoses are for non-muscle invasive bladder cancer (NMIBC), and more than half of these cases relapse after transurethral excision of the bladder tumour. Traditional methods for preventing recurrences include immunotherapy with bacillus Calmette-Guérin (BCG) and
Read More